These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 19651478)

  • 1. Philosophical concerns regarding cost-effectiveness analyses.
    Weiner BK
    Med Hypotheses; 2010 Feb; 74(2):383-6. PubMed ID: 19651478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inexpensive health care reform: the mathematics of medicine.
    Forsyth RA
    Med Hypotheses; 2010 Feb; 74(2):387-8. PubMed ID: 19775823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding cost-effectiveness.
    Zilberberg MD; Shorr AF
    Clin Microbiol Infect; 2010 Dec; 16(12):1707-12. PubMed ID: 20673258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panel on cost-effectiveness in health and medicine recommendations: identifying costs.
    Manning WG
    J Clin Psychiatry; 1999; 60 Suppl 3():54-6; discussion 57-8. PubMed ID: 10073379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic aspects of clinical decision making: applications in patient care.
    Oster G
    Am J Hosp Pharm; 1988 Mar; 45(3):543-7. PubMed ID: 3130753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Problems in interpreting cost effectiveness in clinical trials. Experimental versus implementation costs.
    De Nino LA; Mulrow CD; Gerety MB; Averyt EC
    Online J Curr Clin Trials; 1993 Apr; Doc No 44():[4864 words; 42 paragraphs]. PubMed ID: 8306003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus. Hannover Consensus Group].
    Med Klin (Munich); 2000 Jan; 95(1):52-5. PubMed ID: 10668346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus.
    Graf von der Schulenburg JM; Greiner W; Jost F; Klusen N; Kubin M; Leidl R; Mittendorf T; Rebscher H; Schoeffski O; Vauth C; Volmer T; Wahler S; Wasem J; Weber C;
    Value Health; 2008; 11(4):539-44. PubMed ID: 18194408
    [No Abstract]   [Full Text] [Related]  

  • 12. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold.
    Birch S; Gafni A
    J Health Serv Res Policy; 2006 Jan; 11(1):46-51. PubMed ID: 16378532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care program.
    Slutsky J; Atkins D; Chang S; Sharp BA
    J Clin Epidemiol; 2010 May; 63(5):481-3. PubMed ID: 18834715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of age on cost-effectiveness ratios and its control in decision making.
    Baltussen R; Leidl R; Ament A
    Health Econ; 1996; 5(3):227-39. PubMed ID: 8817297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in economic outcomes research.
    Cook JR
    Hepatology; 1999 Jun; 29(6 Suppl):23S-25S. PubMed ID: 10386079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding cost-effectiveness in the ICU.
    Zilberberg MD
    Semin Respir Crit Care Med; 2010 Feb; 31(1):13-8. PubMed ID: 20101543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis in oncology.
    Evans WK
    Praxis (Bern 1994); 2000 Mar; 89(12):492-6. PubMed ID: 10771589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Introduction to methods of economic modelling: a primer for orthopaedic surgeons and traumatologists].
    Vavken P; Dorotka R
    Z Orthop Unfall; 2009; 147(4):419-23. PubMed ID: 19771671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.